Abbreviations: BHR, bronchial hyperresponsiveness; BHRQ, bronchial hyperresponsiveness quotient; DRS, dose-response slope; FEF75, forced expiratory flow at 75% of FVC; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PC20, provocative concentration leading to a fall in FEV1 of 20%; PD20, provocative dose leading to a fall in FEV1 of 20%.
| INTRODUC TI ON
The prevalence of allergic diseases especially asthma and rhinitis has been increasing in most industrialized and many developing countries. 1 Asthma and allergic rhinitis are mostly considered separately in clinical as well as population-based research settings, but they coexist, a concept termed multimorbidity, more often than expected by chance alone. Few studies examined the longitudinal course of parent-/self-reported single and coexisting allergies in childhood and adolescence. [2] [3] [4] [5] The courses of lung function parameters in multimorbidity subjects in birth cohorts are poorly understood. 6 Although the pathway for asthma involving allergic sensitization, airway inflammation, and bronchial hyperresponsiveness is partly known, the role of lung function parameter and challenging testing in clinically co-occurring allergic entities is not fully understood.
However, its clinical relevance has been increasingly recognized in daily practice. The severity of airway obstruction is determined as part of the diagnosis of asthma by respiratory function tests. These tests are objective measures of airflow limitation, assessing bronchial hyperresponsiveness and reversibility. 7, 8 We therefore aimed to assess the association between resting lung function parameters and bronchial hyperresponsiveness with multimorbidity compared to asthma or rhinitis only and no respiratory allergy in early and late school age as well as young adulthood in a prospective German birth cohort study.
| ME THODS

| Study design, setting, and participants
The first German observational birth cohort study on asthma and allergies, the Multicenter Allergy Study (MAS-90), was initiated in 1990 with 1,314 newborns recruited from six obstetrics departments.
Details of recruitment have been published earlier. 9 Participants
were assessed at 19 time points through questionnaires and interviews, physical examination, allergy blood tests, resting lung function tests, and different bronchial provocation methods. The overall aim of the MAS birth cohort study has been to assess the natural history and influential factors of asthma, allergic rhinoconjunctivitis, atopic dermatitis, allergic sensitization, and impaired lung function.
In this study, we included participants who both responded (i) to the screening questions for asthma and (ii) performed lung function tests at 7, 13, and/or 20 years.
| Definition of asthma, rhinitis, and multimorbidity
Classification of multimorbidity was based on standardized parentand self-reported questions that have been suggested by European population-based birth cohort studies on asthma and allergies. 10 Questions on typical symptoms have been developed and validated in the International Study of Asthma and Allergy in Childhood (ISAAC) project in many languages worldwide. 11, 12 Questionnaires were completed by parents at age 7, by parents and children together at age 13, and by participants at age 20 years.
Current asthma for each of the follow-up time points was defined by reporting at least two of the following three criteria: (i) a parent-reported physician's diagnosis of asthma (ever), (ii) current wheezing (in last 12 months), and/or (iii) current asthma medication (in last 12 months). At age 7 years, current medication was not assessed, limiting criteria for asthma to (i) and (ii), which both had to be present for current asthma.
Current rhinitis for each follow-up time point was defined using stringent epidemiological criteria based on ISAAC criteria as follows:
sneezing, or a runny, or a blocked nose without having a cold or the flu within the past 12 months. 13 Current multimorbidity for each of the follow-up time points was defined as the coexistence of current asthma and current rhinitis.
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| Resting lung function tests
At the age of 7, 13, and 20 years, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and forced expiratory flow at 75% (FEF75) of the exhaled FVC were measured before provocation.
particularly associated with multimorbidity. At the age of 20 years, participants with multimorbidity showed a clearly higher severity in hyperresponsiveness compared to participants who suffered only asthma (P = .049) or rhinitis (P = .008) or were asymptomatic (P < .001).
Conclusion:
Single lung function measurements from childhood ongoing do not seem to discriminate between subjects with multimorbidity, single allergies, and no allergy.
Our results show that multimorbidity is associated with more severe symptoms compared to those suffering only a single allergic disease.
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The same type of spirometer and body plethysmograph was used (Master-Lab, Cardinal Health, Würzburg, Germany) in all centers by trained study nurses and supervised by study physicians.
Participants had to withdraw β 2 -agonists for at least 12 hours and sodium cromoglycate for 48 hours before visiting the study center.
Fourteen participants currently taking inhaled corticosteroids were excluded from the present analyses at age 20 years.
| Bronchial challenge tests
At the age of 7 years, a multistep bronchial histamine challenge was performed, following Matthys et al. 14 At the age of 13 years, a single-step bronchial challenge with cold dry air was performed using the respiratory heat exchange system (RHES; E. Jaeger GmbH, Würzburg, Germany), following Zach et al's 15 procedure required a hyperventilation (at 75% of the maximum voluntary ventilation) with air tempered at −15°C over 4 minutes. To ensure isocapnia, the air was mixed with 5% CO 2 .
At the age of 20 years, a multistep bronchial methacholine challenge was conducted following American Thoracic Society (ATS) guidelines (Pari Provocation Test 2 nebulizer, Starnberg, Germany). 16 We used a single concentration of 3.3 mg/mL with controlled tidal breathing. Methacholine was delivered in five incremental doses 
| Statistical methods
| Transformation of lung function parameters
All lung function parameters were expressed as percentage predicted (pred.), according to Zapletal 17 in children aged 7 and 13 years, and using GLI 2012 reference equation 18 at age 20 years.
Spirometric baseline parameters below 10% or above 200% were considered invalid. Relative differences were computed by considering raw lung function values. Results of provocation measurements were defined as FEV1 and FEF75 after the last provocation dose given.
| PC20/PD20
PC20 as the concentration causing a fall in FEV1 of 20% in histamine challenge and PD20 as the dose causing a fall of FEV1 of exactly 20%
in methacholine challenge were both calculated by linear interpolation between the last and pre-last dose given.
| Bronchial hyperresponsiveness
In histamine challenge, bronchial hyperresponsiveness was defined by a fall in FEV1 of minimum −20%. This corresponds to a PC20 ≤ 1.0 mg/mL. 19 In cold air challenge, a fall in FEV1 of minimum −9% was defined as hyperresponsive. In methacholin challenge, bronchial hyperresponsiveness was defined by a fall in FEV1 of minimum −20% corresponding to a PD20 ≤ 470.6 μg.
| Bronchial hyperresponsiveness quotient (BHRQ)
As a quantitative measure for the severity of bronchial hyperresponsiveness and for comparing different methods of provocation (eg, histamine vs. methacholine challenge), we calculated a bronchial hyperresponsiveness quotient (BHRQ) as an estimate for the observed fall in FEV1 in relation to the highest dose/concentration given. We aimed at a standardized measure with a value of 1 indicating a fall to the exact cutoff at the highest dose. Therefore, the fall in FEV1 was divided by the specific cutoff (in this case: −20%) and the applied dose step was divided by the critical dose step at which hyperresponsiveness was defined (ie, step 4 at age 7 years, and step 5 at age 20 years).
The BHRQ allows a better comparability and is more intuitively interpretable as the regular dose-response slope. A BHRQ of less than 1 indicates that the specific cutoff was not reached, whereas a BHRQ higher than 1 indicates a fall below the cutoff before or at the critical dose step. The higher the BHRQ, the higher the severity of bronchial hyperresponsiveness can be estimated. Therefore, the BHRQ allows an assessment of bronchial obstruction more independent of the applied challenging procedure.
| Association between allergic phenotypes and lung function parameters
Effect size and distribution of metric lung function parameters (baseline and provocation data) by nominal state of multimorbidity ("asymptomatic," "asthma only," "rhinitis only," "asthma plus rhinitis") were estimated by eta-squared (η², range 0 to 1) and analysis BHRQ = (Fall in FEV1/cutoff criterium) (Applied dose step/critical dose step) of variance (ANOVA). For bronchial hyperresponsiveness (dichotomous), we calculated Cramer's V (range 0 to 1). Eta-squared (metric) and chi-squared test (dichotomous) were used to analyze correlations between allergic phenotypes and lung function parameters, as well as calculating P-values (testing "no association"). Two-sided P-values of minimum .05 were considered as statistically significant. For estimating the differences in means of lung function parameters by allergic phenotypes, one-way ANOVA was used by regarding contrasts. We considered one-sided P-values for testing hypotheses such as "multimorbidity leads to lower baseline FEV1 compared to asthma only".
Levene's test was used to assess the equality of variances.
The analyses were performed using IBM SPSS Statistics (version 23.0.0.0, 64-Bit). Venn diagrams were constructed using Venn diagram plotter by integrative omics (version 1.5.5228.29250).
| RE SULTS
| Study population
Of 1314 children recruited to MAS, full lung function assessment was documented for 60.6% at the age of 7 years, 51.3% at the age of 13 years, and 42.6% at the age of 20 years. The distributions of parental educational level, smoking, and their allergies were similar in all analyzed samples, whereas the participants themselves were slightly more often allergic than those in the total cohort were (Table 1) .
| Prevalence of asthma, rhinitis, and multimorbidity
The prevalence of multimorbidity (current asthma plus rhinitis) is more than doubled from age 7 to 13 years and remained at nearly 8% in young adulthood. At each time point, the prevalence of multimorbidity was higher than the prevalence of current asthma without rhinitis, which gradually decreased with age. On the contrary, current rhinitis only was most prevalent of all 3 outcomes and increased substantially with age, affecting over 40% of all participants at the age of 20 years ( Figure 1 & Table 2 ).
Multimorbidity in early childhood disappeared less frequently in young adulthood than single asthma, whereas over half of all study participants with multimorbidity at 7 years were still in this group at the age of 20 ( Figure S1 ). of baseline) (Table S1 ).
Furthermore, there were some differences in lung function between children challenged and those not challenged. Children not challenged had slightly less often asthma at the age of 13 years and more often asthma at the age 20 years. Children not challenged had lower baseline FEV1 at the age of 20 years.
| Resting lung functions by phenotype
Analysis of lung function showed significant lower values for subjects with coexisting asthma and rhinitis compared to those who were asymptomatic or had only asthma or only rhinitis. However, there was no lung function parameter systematically associated with allergic phenotypes. At the age of 7 years, multimorbidity was associated with the lowest values in FEV1/FVC compared to all other groups. No significant differences for FEV1 between the groups could be assessed at the age of 7 and 20 years (Table 3) .
| Hyperresponsiveness by phenotype
Data of hyperresponsiveness by fall below the cutoff of PC/PD20
(yes/no) increased the association between all allergic phenotypes and lung function measurement. Bronchial hyperresponsiveness was most frequent in the group of multimorbidity at the age of 7 and 20 years. At the age of 13 years, BHR was more frequent in subjects with asthma only. Comparing the age of 7 and 20 years, the proportion of children with BHR decreased in all groups (Table 4 ).
| Severity of hyperresponsiveness by phenotypes
Bronchial hyperresponsiveness by BHRQ was most severe in the group of multimorbidity compared to asthma only, rhinitis only, and asymptomatic subjects. Although multimorbidity led to higher values in BHRQ, those differences were just significant compared to rhinitis only and asymptomatic subjects at the age of 7 and 13 years.
However, at the age of 20 years, multimorbidity led significantly to the highest values in BHRQ compared to all other groups ( Figure 2 ).
| D ISCUSS I ON
| Main findings
The MAS birth cohort was the first prospective study to analyze the association between lung function data and multimorbidity of asthma and rhinitis at important time points in life course from childhood to early adulthood. The prevalence of asthma as single entity decreased continuously from school age to young adulthood, whereas the prevalence of asthma and rhinitis co-occurring as multimorbidity increased rapidly at around puberty and remained stable up to the age of 20 years. Regarding lung function data, there were no considerable differences between the single and multimorbid phenotypes. On the contrary, using provocation data, we were able to demonstrate significant differences between the four groups.
Compared to asymptomatic and single entities, multimorbidity led to a higher degree in the severity of hyperresponsiveness, especially in young adults. In addition, the multimorbidity group at 20 years had the largest proportion of subjects with BHR. This corresponds to the single bronchial challenge performed in the Norwegian ECA birth cohort at age 16. 
| Comparison with other studies
In our birth cohort, resting lung function parameters differed only slightly between symptomatic and asymptomatic participants and showed no considerable differences between coexisting and single allergic phenotypes. A comparison of these parameters with other birth cohorts is difficult, because of different time points of examination and study design. For example, in contrast to the Norwegian birth cohort, which analyzed period prevalence of multimorbidity between the age of 10 and 16 years, 6 we could not demonstrate an association of resting lung function parameters with multimorbidity compared to no or single allergic entities.
Considering the bronchial challenge with histamine at age of 7 years, the bronchial hyperresponsiveness appears to be much higher in comparison with challenging with cold air or methacholine. Therefore, histamine seems to be more sensitive. Steinbrugger F I G U R E 1 Relative frequencies of current asthma plus rhinitis, current asthma only (without rhinitis co-occurring), current rhinitis only (without asthma co-occurring), and asymptomatic subjects by age. Numbers indicate frequencies in percent (%) et al demonstrated that only half of 128 symptom-and medicationfree pediatric and adolescent asthma patients were hyperresponsive by cold air compared to histamine. 21 Comparing histamine to methacholine, there seems to be no difference in the pharmacological potency of hyperresponsiveness. 22 On the contrary, it is possible that the proportion of participants with hyperresponsiveness decreases with age. However, studies that examine bronchial hyperresponsiveness in population-based birth cohorts are scarce and have yielded conflicting results. Cox et al postulated the different informative value of bronchial hyperresponsiveness in growing children as a matter of different underlying causes. 23 Comparing the results at age 7 and 20 years, the proportion of children with BHR decreased in all groups (Table 4) . This has been shown previously by several studies in children and adults and could be affected by numerous intrinsic or inherent factors, such as airway geometry. [24] [25] [26] With puberty, this effect seems to grow out and environmental factors seem to have a stronger influence.
For assessing the severity of BHR and comparing different provocation methods, we calculated the new parameter BHRQ, which considers in its formula the clinical cutoffs of provocation doses and the critical decrease in FEV1. Other measures such as the dose-response slope (DRS) are comparable to the BHRQ. The DRS is a widely used parameter which reflects the fall in FEV1 per unit substance inhaled. 27, 28 In addition, some studies have shown that DRS is associated with asthma symptoms and diagnosis. [29] [30] [31] However, the DRS TA B L E 2 Frequency of current asthma and rhinitis as single entity and multimorbidity by follow-up Effect sizes for group mean differences by eta-squared. P-value indicates significant and non-significant mean differences by allergy status.
TA B L E 4
Presence of hyperresponsiveness (yes/no) by allergic status at three time points of follow-up with lung function assessments in the prospective MAS birth cohort In summary, in our birth cohort, bronchial hyperresponsiveness was similarly increased in asthmatic children regardless if they had coexisting rhinitis or not and irrespective from the subject's age-group and the applied provocation method. After puberty, bronchial hyperresponsiveness was considerably worse in subjects with multimorbidity than in those who had only asthma or rhinitis or no allergies.
Although not showing considerable differences in resting lung function measurements, multimorbidity as compared to single allergic entities showed particularly clear differences in the severity of hyperresponsiveness measured by BHRQ at the age of 20 years.
Regarding the early school age, allergic multimorbid subjects showed already a higher degree of bronchial hyperresponsiveness compared to single entities. This trend became more relevant with increasing age and was statistically significant compared to all other groups in young adulthood. So far we cannot answer from our data whether BHR leads to multimorbidity or whether multimorbidity augments BHR.
| Strengths and limitations
We used stringent epidemiological definitions to assess rhinitis and asthma symptoms, diagnoses, and medications including the widely used and validated suggestions from the ISAAC project and European birth cohort consortia. 12, 13 However, data on severity of the diseases were limited and assessed irregularly over the years and, therefore, was not considered in the present analyses. Furthermore, specific causes of wheezing as viral infections can be a relevant factor especially in preschool age. Unfortunately, these factors were not assessed, and therefore, other determinants of wheezing could not be examined.
The change in provocation methods at different time points made comparisons of frequencies of hyperresponsive subjects difficult. We recognize the potential limitations of using different methods. However, at that time, during our 20-year-long birth cohort, each method was the recommended procedure for bronchial challenge tests. The BHRQ allowed us to compare the different assessments to some degree.
As shown in Table 1 , the share of participants with allergic diseases within the first 6 years was slightly higher among the three follow-up visits than among the initially birth cohort sample. This is probably due to a parent's higher interest in exploring children's diseases and could generate a bias in reporting higher numbers of prevalence of diseases but does not change the results of this study by itself.
Furthermore, there were some differences in lung function between children challenged and those not challenged. Children not challenged had slightly less often asthma at the age of 13 years and more often asthma at the age of 20 years. At age 13, it may be possible that the influence of the parents played a role in a way that they had a bigger interest in exploring their children's diseases. Therefore, children participating at 13 years had more often asthma. At age 20, the participants came alone to the study center and those with asthma may have been concerned about potential uncomfortable effects of a provocation. However, reasons for not participating in provocation tests were not systematically assessed;
therefore, any attempt to explain the rather small difference has to remain speculative and is based on anecdotal evidence from the study staff.
| CON CLUS IONS
Single resting lung function measurements during childhood and early adulthood do not seem to discriminate well between subjects with multimorbidity and single allergies and those without asthma F I G U R E 2 Bronchial hyperresponsiveness quotient (BHRQ) by age and allergy status. P-values in boldface mark statistical significance (onesided). Bronchial hyperresponsiveness was significantly most severe in the group of multimorbidity at the age of 20 y. However, there was just a significant difference at the age of 7 y in comparison with asymptomatic subjects and to rhinitis only and asymptomatic subjects in the age of 13 y or rhinitis. Bronchial hyperresponsiveness, by contrast, was clearly more frequent as well as more severe in subjects with multimorbidity than in those with asthma only or rhinitis only and asymptomatic subjects. This indicates that the severity of specific asthma symptoms as airway obstruction is higher in patients with multimorbidity compared to those without rhinitis co-occurring. Further studies should examine whether the considerable hyperresponsiveness difference between multimorbidity and asthma or rhinitis only remains beyond the age of 20 years. Future population-and patient-based cohort evaluations should also consider the presence of multimorbidity in early childhood as a predictor for developing hyperresponsiveness in adolescence and adulthood.
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